Laurus Labs, Wockhardt and 25 other stocks hit 52-week high; check full list

As many as 27 stocks hit their highest level in 52 weeks on Wednesday, February 5, on the National Stock Exchange of India (NSE), even as the broader markets traded flat.

At 12:00 pm, the benchmark NIFTY 50 index was trading at 23,738.45, up 2 points, or 0.01%. The BSE SENSEX, meanwhile, was trading at 78,431.21, down 147.6 points, or 0.2%.

The volatility index, or India VIX, inched up 0.4% to 14.07. Among the sectoral indices, the Media, Metal, and Oil and Gas indices were the top gainers, with a rally of 1.6-1.8%. Meanwhile, the FMCG and Realty indices were the biggest losers, down 0.8% and 0.6%, respectively.

Here’s a look at the major stocks that touched their 52-week highs on Wednesday, February 5:

Laurus Labs Ltd (52-week high: ₹635.7)

The recent rally was triggered after the US approval of an "emergency humanitarian waiver" that ensured continued access to US-funded HIV treatment across 55 countries. Earlier, the US government had halted the President's Emergency Plan for AIDS Relief (PEPFAR), which would have disrupted the supply of antiviral medications for millions. Laurus Labs promptly clarified last week that a potential funding freeze would not have a significant impact on its business, which provided relief to investors.

Laurus Labs also announced strong December 2024 quarter results last month, with its operating profit margin reaching 20% for the first time in seven quarters.

SRF Ltd (52-week high: ₹2,983.9)

The share price has been rising as a weaker rupee is a positive for the company over the long term. The rupee has breached the 87 per dollar mark this week amid the strengthening of the US currency.

The company also showed signs of demand recovery in Q3FY25 earnings announced last week. For the October-December quarter, SRF reported 7% year-on-year growth in consolidated profit after tax (PAT) to ₹270 crore. Consolidated revenue increased 14% to ₹3,491 crore in Q3FY25 from ₹3,053 crore in the year-ago period.

Wockhardt Ltd (52-week high: ₹1,665)

On Friday, Wockhardt announced a breakthrough with its flagship drug, Zaynich, which achieved the highest-ever efficacy in a global Phase III clinical trial for complicated urinary tract infections. This achievement positions Wockhardt as one of the few Indian pharmaceutical firms to develop and potentially market a global antibiotic product. The company now plans to file a New Drug Application with the USFDA and a Marketing Authorisation Application with the European Medicines Agency.